Loading…
Adenosine deaminase cutoff value when diagnosing tuberculous pleurisy in patients aged 40 years and older
Introduction Tuberculous pleurisy (TBP) is one of the most common manifestations of extra‐pulmonary tuberculosis. In patients aged ≥40 years, a closed needle pleural biopsy is recommended with an adenosine deaminase (ADA) level of 40‐70 U/L. We aim to investigate whether the cutoff value of ADA and...
Saved in:
Published in: | The clinical respiratory journal 2021-01, Vol.15 (1), p.109-115 |
---|---|
Main Authors: | , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Request full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | Introduction
Tuberculous pleurisy (TBP) is one of the most common manifestations of extra‐pulmonary tuberculosis. In patients aged ≥40 years, a closed needle pleural biopsy is recommended with an adenosine deaminase (ADA) level of 40‐70 U/L. We aim to investigate whether the cutoff value of ADA and the cancer ratio in patients with TBP aged ≥40 years is different and determine the effects of both compounded biomarkers on diagnosing TBP.
Materials and Methods
Between 2009 and 2016, the ADA levels were measured in pleural effusions from patients who were admitted to the Chest disease clinic.
Results
Of the 196 patients included in the study, 104 were aged ≥40 years. A significant relationship was found between the serum LDH/pleural ADA (sLDH/pADA) ratio and ADA levels in patients aged >40 years (OR: 0.935 and OR: 1.085, respectively). The model using an ADA value ≥30 and an sLDH/pADA ratio 40 years.
Conclusion
ADA and the sLDH/pADA ratio are simple, cost‐efficient, and obtain fast results and, therefore, are the preferred methods in TBP diagnosis. The diagnosis rate in the present study was 91% using ADA levels in combination with the sLDH/pADA ratio, both of which can be obtained only through thoracentesis. |
---|---|
ISSN: | 1752-6981 1752-699X |
DOI: | 10.1111/crj.13277 |